Anthropic has unveiled its first discovery from a newly revealed wet lab: a novel enzyme system with properties reminiscent of CRISPR. The AI-driven lab, quietly operating since spring 2026, represents a significant expansion into biological research for the company.
TL;DR
- Anthropic's new wet lab has made its first discovery: a novel enzyme system called array-associated reverse transcriptases (ART) with CRISPR-like properties.
- The lab uses AI agents to analyze DNA sequences and identify promising proteins for human scientists to test, marking a new application of AI in biological research.
- This development highlights Anthropic's expansion into life sciences and its potential to accelerate biological discoveries, though it also raises questions about competition and resource allocation in the field.
What happened
Anthropic, known for its AI models like Claude, has launched a human-staffed wet lab in the San Francisco Bay Area. The lab, operational since spring 2026, focuses on tackling overlooked biology problems using AI agents to analyze DNA sequences and identify candidate proteins for human scientists to test.
The lab's first discovery is a novel enzyme system called array-associated reverse transcriptases (ART), which has properties similar to CRISPR. This discovery was made by 950 AI agents that searched a database of DNA sequences for new functions, narrowing down over 200,000 candidates to the 20 most promising.
Anthropic's head of life sciences, Eric Kauderer-Abrams, emphasized that the lab is not focused solely on drug science but could target 'undruggable' conditions. The company also clarified that while AI is a significant part of the process, human scientists are still crucial for real lab work.
Why it matters
This development marks a significant expansion for Anthropic into the life sciences, demonstrating the potential of AI to accelerate biological discoveries. The use of AI agents to analyze DNA sequences and identify promising proteins could lead to faster and more efficient research processes.
However, the launch of this lab also raises questions about competition and resource allocation in the field. Some academics have expressed concerns that AI tools like Claude Science could force researchers to choose between funding AI tokens or trainees, potentially widening the gap between well-funded and underfunded research teams.
Anthropic has stated that it is not competing with pharma and biotech companies that bring drugs to market, but the company's access to big guns beyond the reach of external academics could still pose a challenge to smaller research teams.
Key facts
- Anthropic's new wet lab is located in the San Francisco Bay Area and has been operational since spring 2026.
- The lab's first discovery is a novel enzyme system called array-associated reverse transcriptases (ART) with CRISPR-like properties.
- The discovery was made by 950 AI agents that searched a database of DNA sequences for new functions, narrowing down over 200,000 candidates to the 20 most promising.
- The lab uses AI agents to analyze DNA sequences and identify candidate proteins for human scientists to test.
- Anthropic's head of life sciences is Eric Kauderer-Abrams.
- The discovery was made with a team of six named human scientists and used 210 million tokens.
- Feng Zhang, a CRISPR pioneer, described the discovery as 'genuinely intriguing and merits further investigating'.
- Anthropic has stated that it is not competing with pharma and biotech companies that bring drugs to market.
Context
Anthropic's foray into wet lab biology is part of a broader trend of AI companies expanding into the life sciences. This expansion is driven by the potential of AI to accelerate research processes and make discoveries that would be difficult or impossible with traditional methods.
However, this expansion also raises important questions about competition and resource allocation in the field. As AI tools become more powerful and accessible, there is a risk that they could widen the gap between well-funded and underfunded research teams, potentially leading to a concentration of resources and talent in a few large companies.
It is also worth noting that Anthropic's expansion into the life sciences comes at a time when there are growing calls for better regulation of AI. As AI tools become more powerful and are used in more areas, it will be important to ensure that they are used responsibly and ethically, and that their benefits are widely shared.
